However, subsequent Phase 1/2 clinical trials that use BI 836858 to treat low- and intermediate-1-risk MDS patients failed to meet the expected outcomes, indicating that further exploration is needed for treating MDS through CD33/MDSCs (Table 1) [133]. Here, CD33 is linked to myelodysplastic syndrome.